Cash for CA stem cell co's

Six California stem cell biotech companies received more than $5 million in funding last week from the state's stem cell funding body -- the California Institute for Regenerative Medicine (CIRM), according to a linkurl:news release ;http://www.cirm.ca.gov/pdf/ICOC_121008.pdf from the agency. The money represents the first major pay out to companies from the state's $3 billion research enterprise. Until now, only Novocell Inc. had received a small grant of $50,000. The grants are part of 23 gr

Written byAndrea Gawrylewski
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Six California stem cell biotech companies received more than $5 million in funding last week from the state's stem cell funding body -- the California Institute for Regenerative Medicine (CIRM), according to a linkurl:news release ;http://www.cirm.ca.gov/pdf/ICOC_121008.pdf from the agency. The money represents the first major pay out to companies from the state's $3 billion research enterprise. Until now, only Novocell Inc. had received a small grant of $50,000. The grants are part of 23 grants and nearly $20 million awarded to California institutions for the development of tools and technologies to overcome barriers in stem cell research. Three companies who weren't awarded money filed petitions last week as the
working group was finalizing its granting decisions, complaining that the grant allocations were biased toward academic institutions. CIRM
President Alan Trounson, however, said he could not find "compelling evidence" to change the score of any of the applications, or the decision of the CIRM working group that allocates the funding, according to linkurl:The California Stem Cell Report;.http://californiastemcellreport.blogspot.com/
 The companies who won the grants are Novocell, VistaGen Therapeutics, Fluidigm Corp., Gamma-Medica Ideas, Novocell Inc., Invitrogen, and Vala Sciences.
**__Related stories:__***linkurl:Calif. stem cell agency back on track?;http://www.the-scientist.com/news/display/53676/
[4 October 2007]*linkurl:CIRM cuts ten grants;http://www.the-scientist.com/blog/display/53978/
[7 December 2007]*linkurl:CIRM to pay for eggs?;http://www.the-scientist.com/blog/display/54506/
[27 March 2008]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies